Ovid Q2 2026 net loss $15M; soticlestat rights sold to Perceptive NewCo for up to $294.5M milestones

Ovid Therapeutics Inc.

Cash $169.8M at June 30, 2026; runway into 2029.
Net loss $15.0M ($0.08/share) vs $4.7M ($0.06) in Q2 2025; R&D spend up to $10.0M.
OV329 Phase 2 FOS study initiated; photosensitivity study testing 5/7/9 mg doses, results near year-end 2026.
Soticlestat global rights assigned to Perceptive NewCo; Ovid eligible for up to $294.5M milestones plus low-to-mid single-digit royalties.
Leadership: Kevin Norrett CBO, Charles Carter CFO, Eliseo Salinas R&D Advisor; warrants exercised for ~$53.9M proceeds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.